Skip to main content

Table 1 Patient characteristics

From: FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort

Characteristic No. of patients %
Patients evaluable 70 100
Age, years   
 Median (range) 65 (32–75)  
Sex   
 Male 41 58.5
 Female 29 41.5
Response to prior chemotherapy   
 Yes 44 63
 No 26 37
Status of primary tumor   
 Resected 25 36
 Unresected 45 64
Tumor histology   
 Diffuse 33 47.2
 Intestinal 29 41.4
 Unknown 8 11.4
ECOG PS   
 0 10 14.5
 1 40 57
 2 20 28.5
Number of metastatic sites   
 1 17 24
 2 32 46
 3 21 30
Site of metastases   
 Liver 48 68.5
 Nodes 41 58.5
 Peritoneum 41 58.5
 Lung 13 18.5
 Bone 6 8.5
PFS under first-line chemotherapy   
 ≥ 6 months 42 60
 < 6 months 28 40
Chemotherapy-free interval   
 > 3 months 38 54
 < 3 months 32 46
  1. Abbreviations: ECOG PS Eastern Cooperative Oncology Group Performance Status.